Precision Oncology in Advanced Pancreatic Cancer.

Contact:

NCT Number:

Protocol:

AAAR6703

Study Status:

Active/Enrolling

Population:

Adult

Phase:

NA

The purpose of this study is to match individual tumors with the drug or drug combinations that are most likely to destroy those tumors. The purpose of using Ruxolitinib, Imatinib, or Capecitabine to treat your pancreas cancer is to determine whether it is safe and effective in stopping pancreas cancer growth in patients who have already received one or two lines of chemotherapy.

Are you Eligible? (Inclusion Criteria)

  • Are you older than 18 years old?
  • Do you have histologically or cytologically confirmed diagnosis of pancreatic ductal adenocarcinoma?
  • Do you have a life expectancy of greater than 3 months?
  • Do you have documented radiographic progression to or documented intolerance of first- or second-line systemic treatment for locally advanced, unresectable or metastastic disease?

Specialty Area(s)

Pancreatic Cancer, Immunotherapy

Principal Investigator

Profile Headshot
  • Director of Medical Oncology and Translational Research for The Pancreas Center

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032